Your browser doesn't support javascript.
loading
Restrictive Versus Permissive Use of Broad-spectrum Antibiotics in Patients Receiving Allogeneic Stem Cell Transplantation and With Early Fever Due to Cytokine Release Syndrome: Evidence for Beneficial Microbiota Protection Without Increase in Infectious Complications.
Weber, Daniela; Hiergeist, Andreas; Weber, Markus; Ghimire, Sakhila; Salzberger, Bernd; Wolff, Daniel; Poeck, Hendrik; Gessner, André; Edinger, Matthias; Herr, Wolfgang; Meedt, Elisabeth; Holler, Ernst.
Affiliation
  • Weber D; Department of Hematology and Oncology, Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
  • Hiergeist A; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany.
  • Weber M; Department of Trauma and Orthopedic Surgery, Barmherzige Brüder Hospital Regensburg, Regensburg, Germany.
  • Ghimire S; Department of Hematology and Oncology, Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
  • Salzberger B; Department of Infection Prevention and Infectious Diseases, University Hospital Regensburg, Regensburg, Germany.
  • Wolff D; Department of Hematology and Oncology, Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
  • Poeck H; Department of Hematology and Oncology, Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
  • Gessner A; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany.
  • Edinger M; Department of Hematology and Oncology, Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
  • Herr W; Department of Hematology and Oncology, Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
  • Meedt E; Department of Hematology and Oncology, Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
  • Holler E; Department of Hematology and Oncology, Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Clin Infect Dis ; 77(10): 1432-1439, 2023 11 17.
Article in En | MEDLINE | ID: mdl-37386935
ABSTRACT

BACKGROUND:

Intestinal microbiome contributes to the pathophysiology of acute gastrointestinal (GI) graft-versus-host disease (GvHD) and loss of microbiome diversity influences the outcome of patients after allogeneic stem cell transplantation (SCT). Systemic broad-spectrum antibiotics have been identified as a major cause of early intestinal dysbiosis.

METHODS:

In 2017, our transplant unit at the university hospital in Regensburg changed the antibiotic strategy from a permissive way with initiation of antibiotics in all patients with neutropenic fever independent of the underlying cause and risk to a restrictive use in cases with high likelihood of cytokine release syndrome (eg, after anti-thymocyte globulin [ATG] therapy). We analyzed clinical data and microbiome parameters obtained 7 days after allogeneic SCT from 188 patients with ATG therapy transplanted in 2015/2016 (permissive cohort, n = 101) and 2918/2019 (restrictive cohort, n = 87).

RESULTS:

Restrictive antibiotic treatment postponed the beginning of antibiotic administration from 1.4 ± 7.6 days prior to 1.7 ± 5.5 days after SCT (P = .01) and significantly reduced the duration of antibiotic administration by 5.8 days (P < .001) without increase in infectious complications. Furthermore, we observed beneficial effects of the restrictive strategy compared with the permissive way on microbiome diversity (urinary 3-indoxylsulfate, P = .01; Shannon and Simpson indices, P < .001) and species abundance 7 days post-transplant as well as a positive trend toward a reduced incidence of severe GI GvHD (P = .1).

CONCLUSIONS:

Our data indicate that microbiota protection can be achieved by a more careful selection of neutropenic patients qualifying for antibiotic treatment during allogeneic SCT without increased risk of infectious complications.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Hematopoietic Stem Cell Transplantation / Microbiota / Graft vs Host Disease Limits: Humans Language: En Year: 2023 Type: Article

Full text: 1 Database: MEDLINE Main subject: Hematopoietic Stem Cell Transplantation / Microbiota / Graft vs Host Disease Limits: Humans Language: En Year: 2023 Type: Article